326 related articles for article (PubMed ID: 21515375)
1. The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease.
Ilijic E; Guzman JN; Surmeier DJ
Neurobiol Dis; 2011 Aug; 43(2):364-71. PubMed ID: 21515375
[TBL] [Abstract][Full Text] [Related]
2. Lower Affinity of Isradipine for L-Type Ca
Ortner NJ; Bock G; Dougalis A; Kharitonova M; Duda J; Hess S; Tuluc P; Pomberger T; Stefanova N; Pitterl F; Ciossek T; Oberacher H; Draheim HJ; Kloppenburg P; Liss B; Striessnig J
J Neurosci; 2017 Jul; 37(28):6761-6777. PubMed ID: 28592699
[TBL] [Abstract][Full Text] [Related]
3. Isradipine attenuates MPTP-induced dopamine neuron degeneration by inhibiting up-regulation of L-type calcium channels and iron accumulation in the substantia nigra of mice.
Wang QM; Xu YY; Liu S; Ma ZG
Oncotarget; 2017 Jul; 8(29):47284-47295. PubMed ID: 28521299
[TBL] [Abstract][Full Text] [Related]
4. The Potential of L-Type Calcium Channels as a Drug Target for Neuroprotective Therapy in Parkinson's Disease.
Liss B; Striessnig J
Annu Rev Pharmacol Toxicol; 2019 Jan; 59():263-289. PubMed ID: 30625283
[TBL] [Abstract][Full Text] [Related]
5. Nimodipine, an L-type calcium channel blocker attenuates mitochondrial dysfunctions to protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice.
Singh A; Verma P; Balaji G; Samantaray S; Mohanakumar KP
Neurochem Int; 2016 Oct; 99():221-232. PubMed ID: 27395789
[TBL] [Abstract][Full Text] [Related]
6. Antagonizing L-type Ca2+ channel reduces development of abnormal involuntary movement in the rat model of L-3,4-dihydroxyphenylalanine-induced dyskinesia.
Schuster S; Doudnikoff E; Rylander D; Berthet A; Aubert I; Ittrich C; Bloch B; Cenci MA; Surmeier DJ; Hengerer B; Bezard E
Biol Psychiatry; 2009 Mar; 65(6):518-26. PubMed ID: 18947822
[TBL] [Abstract][Full Text] [Related]
7. Neuroprotective effects of acetyl-l-carnitine (ALC) in a chronic MPTP-induced Parkinson's disease mouse model: Endothelial and microglial effects.
Burks S; Raymick J; Robinson B; Hanig J; Sarkar S
Neurosci Lett; 2019 Jun; 703():86-95. PubMed ID: 30890473
[TBL] [Abstract][Full Text] [Related]
8. Systemic isradipine treatment diminishes calcium-dependent mitochondrial oxidant stress.
Guzman JN; Ilijic E; Yang B; Sanchez-Padilla J; Wokosin D; Galtieri D; Kondapalli J; Schumacker PT; Surmeier DJ
J Clin Invest; 2018 Jun; 128(6):2266-2280. PubMed ID: 29708514
[TBL] [Abstract][Full Text] [Related]
9. Systemically administered neuregulin-1β1 rescues nigral dopaminergic neurons via the ErbB4 receptor tyrosine kinase in MPTP mouse models of Parkinson's disease.
Depboylu C; Rösler TW; de Andrade A; Oertel WH; Höglinger GU
J Neurochem; 2015 May; 133(4):590-7. PubMed ID: 25581060
[TBL] [Abstract][Full Text] [Related]
10. Cav1.4alpha1 subunits can form slowly inactivating dihydropyridine-sensitive L-type Ca2+ channels lacking Ca2+-dependent inactivation.
Koschak A; Reimer D; Walter D; Hoda JC; Heinzle T; Grabner M; Striessnig J
J Neurosci; 2003 Jul; 23(14):6041-9. PubMed ID: 12853422
[TBL] [Abstract][Full Text] [Related]
11. Neuroprotection in Parkinson models varies with toxin administration protocol.
Anderson DW; Bradbury KA; Schneider JS
Eur J Neurosci; 2006 Dec; 24(11):3174-82. PubMed ID: 17156378
[TBL] [Abstract][Full Text] [Related]
12. Calcium, ageing, and neuronal vulnerability in Parkinson's disease.
Surmeier DJ
Lancet Neurol; 2007 Oct; 6(10):933-8. PubMed ID: 17884683
[TBL] [Abstract][Full Text] [Related]
13. Neuroprotective effect of the chemical chaperone, trehalose in a chronic MPTP-induced Parkinson's disease mouse model.
Sarkar S; Chigurupati S; Raymick J; Mann D; Bowyer JF; Schmitt T; Beger RD; Hanig JP; Schmued LC; Paule MG
Neurotoxicology; 2014 Sep; 44():250-62. PubMed ID: 25064079
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of striatal dopamine release by the L-type calcium channel inhibitor isradipine co-varies with risk factors for Parkinson's.
Brimblecombe KR; Connor-Robson N; Bataille CJR; Roberts BM; Gracie C; O'Connor B; Te Water Naude R; Karthik G; Russell AJ; Wade-Martins R; Cragg SJ
Eur J Neurosci; 2024 Mar; 59(6):1242-1259. PubMed ID: 37941514
[TBL] [Abstract][Full Text] [Related]
15. Antagonism of L-type Ca2+ channels CaV1.3 and CaV1.2 by 1,4-dihydropyrimidines and 4H-pyrans as dihydropyridine mimics.
Kang S; Cooper G; Dunne SF; Luan CH; James Surmeier D; Silverman RB
Bioorg Med Chem; 2013 Jul; 21(14):4365-73. PubMed ID: 23688558
[TBL] [Abstract][Full Text] [Related]
16. The Kv7/KCNQ channel blocker XE991 protects nigral dopaminergic neurons in the 6-hydroxydopamine rat model of Parkinson's disease.
Liu H; Jia L; Chen X; Shi L; Xie J
Brain Res Bull; 2018 Mar; 137():132-139. PubMed ID: 29174294
[TBL] [Abstract][Full Text] [Related]
17. Calcium Channel Antagonists as Disease-Modifying Therapy for Parkinson's Disease: Therapeutic Rationale and Current Status.
Swart T; Hurley MJ
CNS Drugs; 2016 Dec; 30(12):1127-1135. PubMed ID: 27826740
[TBL] [Abstract][Full Text] [Related]
18. L-type voltage-gated calcium channel blockade with isradipine as a therapeutic strategy for Alzheimer's disease.
Anekonda TS; Quinn JF; Harris C; Frahler K; Wadsworth TL; Woltjer RL
Neurobiol Dis; 2011 Jan; 41(1):62-70. PubMed ID: 20816785
[TBL] [Abstract][Full Text] [Related]
19. Small molecule TrkB agonist deoxygedunin protects nigrostriatal dopaminergic neurons from 6-OHDA and MPTP induced neurotoxicity in rodents.
Nie S; Xu Y; Chen G; Ma K; Han C; Guo Z; Zhang Z; Ye K; Cao X
Neuropharmacology; 2015 Dec; 99():448-58. PubMed ID: 26282118
[TBL] [Abstract][Full Text] [Related]
20. Broad neuroprotective profile of nicotinamide in different mouse models of MPTP-induced parkinsonism.
Anderson DW; Bradbury KA; Schneider JS
Eur J Neurosci; 2008 Aug; 28(3):610-7. PubMed ID: 18702732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
